Seres Therapeutics to Share Financial Insights Soon
Seres Therapeutics, Inc. (NASDAQ: MCRB), a pioneer in live biotherapeutics, has exciting news lined up for investors and stakeholders. Management is set to conduct a conference call and live audio webcast to discuss the third quarter financial results and provide key business updates. This discussion is scheduled for a bright morning at 8:30 a.m. ET, where essential insights into the company’s progress will be shared.
Accessing the Conference Call
Participating in the conference call is straightforward. Interested listeners can dial either 800-715-9871 for domestic calls or 646-307-1963 for international connections. When dialing in, it’s important to have the conference ID number 8471287 ready for a smooth entry. Alternatively, for those who prefer an online format, joining the live webcast is as simple as visiting the 'Investors and News' section of Seres Therapeutics' website.
Webcast Replay Availability
For anyone unable to join the discussion live, a replay of the webcast will be readily available shortly after the event. This will be archived on the Seres website for approximately 21 days, offering flexibility for viewers to catch up on what they may have missed.
About Seres Therapeutics
Seres Therapeutics stands out in the biotherapeutics realm, focusing on enhancing the health of medically vulnerable populations through innovative live microbiome therapies. They made headlines recently with their pioneering drug, VOWST™, recognized as the first FDA-approved orally administered microbiome therapeutic. This breakthrough was notably sold to Nestlé Health Science, marking a significant stride in the biotherapeutics industry.
Innovative Pipeline Programs
Currently, Seres is diligently advancing SER-155, which has garnered the prestigious Breakthrough Therapy designation. This therapeutic aims to mitigate bloodstream infections for adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). In clinical trials, SER-155 has shown promising results by significantly lowering the rates of bloodstream infections compared to placebo groups.
Expanding Horizons in Biotherapeutics
Beyond allo-HSCT, SER-155 and other cultivated live biotherapeutic candidates are being evaluated for various medically vulnerable populations. These include patients undergoing autologous-HSCT, individuals suffering from chronic liver disease, and cancer patients facing neutropenia, among others. By leveraging advanced manufacturing techniques from standard clonal cell banks, Seres Therapeutics is committed to addressing complex health challenges.
Contact Information for Investors and Media
Communication with Seres Therapeutics is encouraged through their designated channels. Investors looking for insights or further information can reach out via email at IR@serestherapeutics.com.
Alternatively, Carlo Tanzi, Ph.D. from Kendall Investor Relations is available for inquiries at ctanzi@kendallir.com.
Frequently Asked Questions
1. When is the financial results announcement for Seres Therapeutics?
The financial results announcement will take place on November 5, 2025.
2. How can I access the conference call?
You can access the conference call by dialing 800-715-9871 or 646-307-1963 and using the conference ID number 8471287.
3. What is SER-155 and its significance?
SER-155 is an innovative therapeutic designed to reduce bloodstream infections in patients undergoing allo-HSCT, and it has shown significant results in clinical studies.
4. What product has Seres Therapeutics developed recently?
Seres recently developed VOWST™, which is the first FDA-approved orally administered microbiome therapeutic.
5. How can I contact investor relations for more information?
Investors can reach out via email to IR@serestherapeutics.com for inquiries.
